Mensah Emmanuel O, Abusellie Abdul R, Pringle Catherine, Emsley Hedley, Alalade Andrew F, Roberts Gareth A
School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0SP, UK.
Department of Neurosurgery, Royal Preston Hospital, Preston, PR2 9HT, UK.
Neurosurg Rev. 2023 Oct 9;46(1):266. doi: 10.1007/s10143-023-02168-0.
Perianeurysmal vasogenic oedema (PAVO) is a rare complication associated post-embolisation of intracranial aneurysms. The prevalence, risk factors predisposing to susceptibility, and pathologic mechanisms underlying this process are not clearly understood. Since this complication may be associated with poor clinical outcomes, the authors designed this study to describe possible risk factors, underlying mechanisms, and management of PAVO through published case reports. Developing a priori protocol according to PRISMA guidelines, we searched MEDLINE/PubMed, Embase and Web of Science to identify case studies and reports of adult patients with intracranial aneurysms who developed perianeurysmal oedema following coil embolization therapy. Data extracted from these studies included patient demographics, aneurysm characteristics, coil type, PAVO characteristics, treatment, and outcomes. Quality was assessed using a standardized tool. 21 eligible studies of acceptable quality were identified, comprising 40 unique cases from 9 countries. The mean patient age was 56.4 years and 25 (62.5%) were female. Aneurysm size ranged from 6 to 30 mm, with a mean size of 15.2 mm; only 6 (15%) of cases were giant intracranial aneurysm (≥ 25 mm). The more frequent locations of intracranial aneurysms associated with PAVO were the ICA (50%) and posterior circulation (32.5%), with 7.5% and 10% of cases occurring in MCA and anterior circulation, respectively. 16 cases (40%) were treated with bare platinum coils, and 14 (35%) with a combination of BPCs and bioactive coils; in 10 cases (25%), the coil type was not mentioned. PAVO presented between 0 days and 8 years of coil embolization, with 23 (57.5% cases) presenting symptomatically in relation to brain region affected. Management strategies for PAVO included conservative, steroids, re-embolization, clipping, stenting, parent artery occlusion either as monotherapy or as combination therapy. Of reported studies, 26 treated cases (65%) resolved, with 8 (20%) remaining stable, and 4 (10%) deteriorating. PAVO can be associated with small or large intracranial aneurysms, bare and bioactive platinum coils, and all regions of the intracranial circulation. The understanding of the risk factors of this complication lies in the underlying mechanisms, which will ultimately guide appropriate patient follow-up and subsequent optimal management.
动脉瘤周围血管源性水肿(PAVO)是颅内动脉瘤栓塞术后一种罕见的并发症。其患病率、易患风险因素以及该过程的病理机制尚不清楚。由于这种并发症可能与不良临床结局相关,作者设计了本研究,通过已发表的病例报告来描述PAVO可能的风险因素、潜在机制及管理方法。根据PRISMA指南制定先验方案,我们检索了MEDLINE/PubMed、Embase和Web of Science,以识别接受弹簧圈栓塞治疗后发生动脉瘤周围水肿的成年颅内动脉瘤患者的病例研究和报告。从这些研究中提取的数据包括患者人口统计学信息、动脉瘤特征、弹簧圈类型、PAVO特征、治疗方法及结局。使用标准化工具评估质量。共识别出21项质量可接受的合格研究,包括来自9个国家的40例独特病例。患者平均年龄为56.4岁,25例(62.5%)为女性。动脉瘤大小范围为6至30mm,平均大小为15.2mm;仅6例(15%)为巨大颅内动脉瘤(≥25mm)。与PAVO相关的颅内动脉瘤较常见的位置是颈内动脉(50%)和后循环(32.5%),分别有7.5%和10%的病例发生在大脑中动脉和前循环。16例(40%)使用裸铂弹簧圈治疗,14例(35%)使用裸铂弹簧圈和生物活性弹簧圈联合治疗;10例(25%)未提及弹簧圈类型。PAVO出现在弹簧圈栓塞术后0天至8年之间,23例(57.5%)出现与受影响脑区相关的症状。PAVO的管理策略包括保守治疗、使用类固醇、再次栓塞、夹闭、支架置入、单纯或联合治疗的载瘤动脉闭塞。在已报道的研究中,26例接受治疗的病例(65%)病情缓解,8例(20%)病情稳定,4例(10%)病情恶化。PAVO可与大小不同的颅内动脉瘤、裸铂和生物活性铂弹簧圈以及颅内循环的所有区域相关。对这种并发症风险因素的理解在于其潜在机制,这最终将指导适当的患者随访及后续的最佳管理。